Phát hiện yếu tố tăng trưởng nội mô mạch máu trong các khối u ung thư đại trực tràng sử dụng phức hợp huỳnh quang hồng ngoại gần dựa trên bevacizumab

Weissleder R, Mahmood U: Molecular imaging. Radiology. 2001, 219: 316-333. 10.1148/radiology.219.2.r01ma19316. Herschman HR: Molecular imaging: looking at problems, seeing solutions. Science. 2003, 302: 605-608. 10.1126/science.1090585. Paudyal B, Zhang K, Chen CP, Wampole ME, Mehta N, Mitchell EP, Gray BD, Mattis JA, Pak KY, Thakur ML, Wickstrom E: Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. Nucl Med Biol. 2013, 40: 994-999. 10.1016/j.nucmedbio.2013.08.005. Paudyal B, Oriuchi N, Paudyal P, Tsushima Y, Iida Y, Higuchi T, Hanaoka H, Miyakubo M, Takano A, Ishikita T, Endo K: Early diagnosis of recurrent hepatocellular carcinoma with 18 F-FDG PET after radiofrequency ablation therapy. Oncol Rep. 2007, 18: 1469-1473. Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K: Clinical implication of glucose transport and metabolism evaluated by 18 F-FDG PET in hepatocellular carcinoma. Int J Oncol. 2008, 33: 1047-1054. Paudyal P, Paudyal B, Hanaoka H, Oriuchi N, Iida Y, Yoshioka H, Tominaga H, Watanabe S, Ishioka NS, Endo K: Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. Cancer Sci. 2010, 101: 1045-1050. 10.1111/j.1349-7006.2010.01480.x. Hoffman RM: The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer. 2005, 5: 796-806. 10.1038/nrc1717. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, Sevick-Muraca EM, Li C: Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 2003, 63: 7870-7875. Weissleder R, Ntziachristos V: Shedding light onto live molecular targets. Nat Med. 2003, 9: 123-128. 10.1038/nm0103-123. Klohs J, Wunder A, Licha K: Near-infrared fluorescent probes for imaging vascular pathophysiology. Basic Res Cardiol. 2008, 103: 144-151. 10.1007/s00395-008-0702-7. Paudyal P, Paudyal B, Iida Y, Oriuchi N, Hanaoka H, Tominaga H, Ishikita T, Yoshioka H, Higuchi T, Endo K: Dual functional molecular imaging probe targeting CD20 with PET and optical imaging. Oncol Rep. 2009, 22: 115-119. Mahmood U, Tung CH, Bogdanov A, Weissleder R: Near-infrared optical imaging of protease activity for tumor detection. Radiology. 1999, 213: 866-870. 10.1148/radiology.213.3.r99dc14866. Chang SK, Rizvi I, Solban N, Hasan T: In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res. 2008, 14: 4146-4153. 10.1158/1078-0432.CCR-07-4536. Zhu Q, Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman SH: Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia. 2008, 10: 1028-1040. Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W: Positron Emission Tomography and Near-Infrared Fluorescence Imaging of Vascular Endothelial Growth Factor with Dual-Labeled Bevacizumab. Am J Nucl Med Mol Imaging. 2012, 2: 1-13. Thakur ML, Zhang K, Paudyal B, Devakumar D, Covarrubias MY, Chen CP, Gray BD, Wickstrom E, Pak KY: Targeting apoptosis for optical imaging of infection. Mol Imaging Biol. 2012, 14: 163-171. 10.1007/s11307-011-0490-6. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schroder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG: Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 2011, 52: 1778-1785. 10.2967/jnumed.111.092833. Leevy WM, Lambert TN, Johnson JR, Morris J, Smith BD: Quantum dot probes for bacteria distinguish Escherichia coli mutants and permit in vivo imaging. Chem Commun (Camb). 2008, 20: 2331-2333. Pierce MC, Javier DJ, Richards-Kortum R: Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int J Cancer. 2008, 123: 1979-1990. 10.1002/ijc.23858. Bremer C, Ntziachristos V, Weissleder R: Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol. 2003, 13: 231-243. Withrow KP, Newman JR, Skipper JB, Gleysteen JP, Magnuson JS, Zinn K, Rosenthal EL: Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts. Technol Cancer Res Treat. 2008, 7: 61-66. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13: 9-22. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993, 53: 4727-4735. Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, Endo K: Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci. 2011, 102: 117-121. 10.1111/j.1349-7006.2010.01763.x. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971, 285: 1182-1186. 10.1056/NEJM197111182852108. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004, 3: 391-400. 10.1038/nrd1381. Gasparini G, Longo R, Fanelli M, Teicher BA: Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol. 2005, 23: 1295-1311. 10.1200/JCO.2005.10.022. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350: 2335-2342. 10.1056/NEJMoa032691. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY: Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer. 1996, 32A: 2474-2484. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med. 2003, 9: 669-676. 10.1038/nm0603-669. Stollman TH, Scheer MG, Leenders WP, Verrijp KC, Soede AC, Oyen WJ, Ruers TJ, Boerman OC: Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer. 2008, 122: 2310-2314. 10.1002/ijc.23404. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN: In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007, 48: 1313-1319. 10.2967/jnumed.107.041301. Abbas Rizvi SM, Song EY, Raja C, Beretov J, Morgenstern A, Apostolidis C, Russell PJ, Kearsley JH, Abbas K, Allen BJ: Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206. Cancer Biol Ther. 2008, 7: 1547-1554. 10.4161/cbt.7.10.6538. Scheer MG, Stollman TH, Boerman OC, Verrijp K, Sweep FC, Leenders WP, Ruers TJ, Oyen WJ: Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. Eur J Cancer. 2008, 44: 1835-1840. 10.1016/j.ejca.2008.05.026. Jain RK: Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999, 1: 241-263. 10.1146/annurev.bioeng.1.1.241. Fujimori K, Covell DG, Fletcher JE, Weinstein JN: A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med. 1990, 31: 1191-1198. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001, 61: 4750-4755.